Arca Biopharma | ABIO - Equity Capital And Reserves


Arca Biopharma reported $486.72M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Alterity Therapeutics Limited AUD 36.21M 18.58M Dec/2025
Amgen USD 9.19B 532M Mar/2026
Arca Biopharma USD 486.72M 17.72M Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
Brainstorm Cell Therapeutics USD -11.01M 1.02M Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Capricor Therapeutics USD 278.7M 27.09M Mar/2026
Cipla INR 344.32B 15.13B Mar/2026
Clal Biotechnology ILS 121.41M 4.62M Dec/2023
Compugen USD 102.73M 58.9M Dec/2025
CSL USD 18.66B 2.75B Dec/2025
Cytokinetics USD -826.57M 166.94M Mar/2026
Daiichi Sankyo JPY 1.71T 57.86B Dec/2025
Gilead Sciences USD 23.52B 897M Mar/2026
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Grifols EUR 6.21B 133.12M Dec/2025
Laboratory Of America USD 8.73B 108.8M Mar/2026
Myriad Genetics USD 337.4M 30.6M Mar/2026
Otsuka Holdings JPY 3.11T 74.63B Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
United Therapeutics USD 5.9B 1.2B Mar/2026